Mark Offer

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis

Ashutosh Wechalekar, Hugh J. B. Goodman, Helen J. Lachmann et al. · Blood · 2006 · 231 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +3

Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis

Julian D. Gillmore, Glenys A. Tennent, Winston L. Hutchinson et al. · British Journal of Haematology · 2010 · 138 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis

Julian D. Gillmore, Hugh J. B. Goodman, Helen J. Lachmann et al. · Blood · 2005 · 131 citations · Full text

Medicine, Cardiology, Internal Medicine +11

Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease

Ashutosh Wechalekar, Helen J. Lachmann, Mark Offer et al. · Haematologica · 2008 · 131 citations · Full text

Medicine, Oncology, Pharmacology +10

Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation

Ashutosh Wechalekar, Mark Offer, Julian D. Gillmore et al. · Nature Clinical Practice Cardiovascular Medicine · 2008 · 22 citations

Medicine, Cardiology, Pathology +12